ライフサイエンスコーパス: neuropathic

1 In addition, GI pain can be nociceptive, neuropathic and associated with cancer, but in many case

2 6-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models.

3 ipherally induced nociception and alleviated neuropathic and inflammatory pain.

4 iceptive efficacy and tolerance in models of neuropathic and/or inflammatory pain.

5 ions, including postoperative, inflammatory, neuropathic, and migraine pain, as well as opioid-induce

6 WT neuropathic animals showed signs of spontaneous pain and

7 Neuropathic breast pain did not differ by anaesthetic te

8 In cohort 3, we assessed the presence of neuropathic characteristics of pain.

9 quarters of patients presented with pain of neuropathic characteristics, which had a length-dependen

10 pain, originating from both inflammatory and neuropathic components, and compounds able to modulate t

11 itudinal, prospective study of patients with neuropathic diabetic foot ulcers (DFU).

12 possible effective treatment option for the neuropathic forms of Gaucher disease.

13 sensitization, attenuating inflammatory and neuropathic hyperalgesia.

14 inals in simulated models of inflammatory or neuropathic hyperexcitability led to a change in the tem

15 deletion of miR-21 in sensory neurons reduce neuropathic hypersensitivity as well as the extent of in

16 g and significantly reduced inflammatory and neuropathic hypersensitivity.

17 Samples from age-matched non-neuropathic individuals were used as controls.

18 The human ENS expresses risk genes for neuropathic, inflammatory, and extra-intestinal diseases

19 order convey mechanical allodynia induced by neuropathic injuries.

20 Pain sensitivity both acutely and following neuropathic injury was largely unaffected by HCN3 deleti

21 ing a new contributor to the pathogenesis of neuropathic itch and identifying a new candidate therape

22 ines, activity-induced genes, and markers of neuropathic itch.

23 ed target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher's

24 Neuropathic lysosomal storage disorders (LSDs) present w

25 h L3 and L4 nerves completely alleviated all neuropathic manifestations.

26 sciatic nerve and the dorsal root ganglia in neuropathic mice.

27 sufficient to produce pain-like behaviors in neuropathic mice.SIGNIFICANCE STATEMENT Mechanical allod

28 of LXR pathways have been identified in many neuropathic models.

29 between eIF2alpha and the MEK/ERK pathway in neuropathic nerves.SIGNIFICANCE STATEMENT In the P0S63de

30 nt relief from nociceptive, inflammatory and neuropathic nociception and offers a much-needed non-opi

31 mice in either development or maintenance of neuropathic nociception in either neuropathic pain model

32 ts with diabetes with neuroischaemic (NI) or neuropathic (NP) foot ulcers.

33 h other causes for ulcers, including venous, neuropathic, or pressure changes.

34 of inflammatory origin (atopic dermatitis), neuropathic origin (brachioradial pruritus), and chronic

35 , with a focus on diabetic osteomyelitis and neuropathic osteoarthropathy.

36 eatment and control groups for patients with neuropathic pain (-0.1 points [95% CI, -0.8 to 0.5 point

37 ry, emotional, and cognitive consequences of neuropathic pain (chronic constriction injury) in a rat

38 positive nociceptors in chemotherapy-induced neuropathic pain (CIPN) caused by paclitaxel treatment.

39 Although NIBS can alleviate neuropathic pain (including PLP), both disease and treat

40 Pain creams compounded for neuropathic pain (ketamine, gabapentin, clonidine, and l

41 Neuropathic pain (NeuP) arises due to injury of the soma

42 Neuropathic pain (NP) is a complex chronic pain state wi

43 icated in neuronal excitation, seizures, and neuropathic pain (NP).

44 s and a collection of TDPs in a rat model of neuropathic pain according to a longitudinal, double-bli

45 ions for therapeutics.SIGNIFICANCE STATEMENT Neuropathic pain affects up to 10% of the population, bu

46 Neuropathic pain afflicts millions of individuals and re

47 and peripheral electrical NINMs could reduce neuropathic pain among DPN patients, without reported ad

48 ng contributes to various diseases including neuropathic pain and drug addiction.

49 As a result, attenuation of ocular neuropathic pain and dry eye will take place.

50 ular mechanisms engaged by the S1PR1 axis in neuropathic pain and establish S1PR1 as a target for the

51 ciated with the emergence and maintenance of neuropathic pain and increased pin-prick sensation.

52 ed nerve injury replicates symptoms of human neuropathic pain and induces upregulation of many genes

53 Its key role in neuropathic pain and its limited cellular and tissue dis

54 first-line treatment in chemotherapy-induced neuropathic pain and may be highly efficacious in neurop

55 es could serve as neuroimaging biomarkers of neuropathic pain and might be used for prediction and mo

56 which are associated with the persistence of neuropathic pain and motor dysfunction.

57 se review of the role of dendritic spines in neuropathic pain and outline the potential for modulatio

58 ession, however, has been largely limited to neuropathic pain and perineural invasion.

59 ess behaviour), post-surgical pain, diabetic neuropathic pain and post-herpetic pain.

60 nize GPR160, identify it as a determinant of neuropathic pain and potential therapeutic target, and p

61 fibre damage in relation to the severity of neuropathic pain and quality of life (QoL) in patients w

62 anglion neurons is associated with radicular/neuropathic pain and radiographic nerve root compression

63 berrant afferent input in the maintenance of neuropathic pain and the potential for targeted chemogen

64 , and led to robust motosensory improvement, neuropathic pain and tissue damage mitigation, and myeli

65 play a critical role in mPFC deactivation in neuropathic pain and underlie the mPFC-specific cognitiv

66 Sensory problems such as neuropathic pain are common and debilitating symptoms in

67 Here, we show that both basal mechanical and neuropathic pain are controlled by the microRNA-183 (miR

68 ved in axon growth, whereas genes related to neuropathic pain are decreased.

69 The mechanisms underlying neuropathic pain are poorly understood.

70 Non-opioid therapeutics for the treatment of neuropathic pain are urgently needed to address the ongo

71 P2, and DPP10 are potential drug targets for neuropathic pain because they form a channel complex wit

72 plays a critical role in CeA plasticity and neuropathic pain behaviors in the rat spinal nerve ligat

73 al efficacy of nicotinic agents in relieving neuropathic pain best correlated with their activity on

74 showed that they reduce oxaliplatin-induced neuropathic pain by a mechanism involving the alpha7 sub

75 dings support a model in which PI16 promotes neuropathic pain by mediating a cross-talk between fibro

76 inal cord in response to nerve injury drives neuropathic pain by selectively activating the S1P recep

77 Neuropathic pain can be a debilitating condition with bo

78 vel translational circuit for the genesis of neuropathic pain caused by chemotherapy with important i

79 Neuropathic pain caused by nerve injury presents with se

80 Neuropathic pain caused by peripheral nerve injuries sig

81 In the neuropathic pain condition, Homer1a, an activity-depende

82 nociceptor sensitization in inflammatory and neuropathic pain conditions.

83 he daily rhythmicity of pain sensation under neuropathic pain conditions.

84 not MMP-2/-12/-14 and significantly relieved neuropathic pain development in mice.

85 specific proteins during distinct phases of neuropathic pain development produces enhanced antinocic

86 golipid metabolism alterations contribute to neuropathic pain development.

87 onic non-freezing cold injury is a disabling neuropathic pain disorder due to a sensory neuropathy.

88 istent post-surgical pain, fibromyalgia, and neuropathic pain disorders, is highly prevalent but rema

89 ntagonists retained their ability to inhibit neuropathic pain during sustained drug administration, a

90 esting paradigms for determining preclinical neuropathic pain efficacy and point to the MNK inhibitor

91 on mechanical allodynia, a standard test for neuropathic pain efficacy.

92 Neuropathic pain encompasses a diverse array of clinical

93 Neuropathic pain features were present in 50% (95% CI, 3

94 e-specific knockout of S1pr1 did not develop neuropathic pain following nerve injury, thereby identif

95 spinal nerves may be used to manage chronic neuropathic pain following peripheral nerve injury.

96 erlying cause for the development of chronic neuropathic pain following SCI.

97 type channels in SCI-nociceptors and chronic neuropathic pain following SCI.

98 erexcitable state and contributes to chronic neuropathic pain following SCI.SIGNIFICANCE STATEMENT Ch

99 critical role in the development of chronic neuropathic pain following spinal cord injury (SCI).

100 Our findings reveal a novel mechanism of neuropathic pain formation and highlight MrgprD as a pro

101 Neuropathic pain frequently leads to decisions about usi

102 acts as the de novo DNMT and is required for neuropathic pain genesis likely through repressing at le

103 hypersensitivities, DRG DNMT1 contributes to neuropathic pain genesis partially through repression of

104 mary sensory neurons of DRG are critical for neuropathic pain genesis.

105 om molecular discoveries in animal models of neuropathic pain have failed to translate following unsu

106 citatory dorsal horn interneurons facilitate neuropathic pain hypersensitivity.

107 ch as paclitaxel are known to elicit chronic neuropathic pain in cancer patients and seriously compro

108 knowledge of the mechanisms contributing to neuropathic pain in diabetes.

109 venues and that has the potential to predict neuropathic pain in future cohorts.

110 lular determinants of nerve regeneration and neuropathic pain in humans.

111 on in the spinal cord prevented and reversed neuropathic pain in male and female rodents without alte

112 nic pain, and notably in oxaliplatin-induced neuropathic pain in mice.

113 s of colorectal carcinoma, causes peripheral neuropathic pain in patients.

114 t not agonists, attenuated and even reversed neuropathic pain in rodents of both sexes and in two mod

115 B2) agonist, suppresses chemotherapy-induced neuropathic pain in rodents without producing tolerance

116 ding to altered sensory phenotypes including neuropathic pain in SFN.SIGNIFICANCE STATEMENT This work

117 Symptomatic treatment of neuropathic pain in small fibre neuropathy is often disa

118 vidence suggests that cannabis may alleviate neuropathic pain in some patients, but insufficient evid

119 n a well-established mouse model of diabetic neuropathic pain in vivo film implantation showed effect

120 Pin-prick score of the 25 patients with neuropathic pain increased from 1 to 12 months (Deltamea

121 We show that chronic neuropathic pain increases PACAP expression at multiple

122 The spared nerve injury (SNI) model of neuropathic pain increases PI16 protein levels in fibrob

123 expression of Cdk5 in a preclinical model of neuropathic pain increases the functional expression of

124 nociceptors in naive mice and at the peak of neuropathic pain induced by paclitaxel treatment.

125 phrine, TNFalpha, and interleukin-6, and the neuropathic pain induced by the cancer chemotherapy pacl

126 Identifying the molecular players underlying neuropathic pain induced structural and functional malad

127 nth is the strongest predictor for 12 months neuropathic pain intensity (1.90+/-2.26 and 3.83+/-1.19,

128 tions, drug discovery, prosthetic design and neuropathic pain investigations.

129 Neuropathic pain is a complex, chronic pain state that o

130 ced tactile allodynia.SIGNIFICANCE STATEMENT Neuropathic pain is a current public health challenge.

131 Neuropathic pain is a debilitating condition caused by t

132 following SCI.SIGNIFICANCE STATEMENT Chronic neuropathic pain is a major comorbidity of spinal cord i

133 Neuropathic pain is a significant public health challeng

134 Neuropathic pain is an intractable medical condition wit

135 Neuropathic pain is believed to arise from damage to noc

136 Treating neuropathic pain is challenging and novel non-opioid-bas

137 Neuropathic pain is common in peripheral neuropathy.

138 echanisms responsible for the maintenance of neuropathic pain is imperative for the development of mo

139 a primary dermatological disorder can cause neuropathic pain is still unclear.

140 vealing potential peripheral DRG targets for neuropathic pain management.

141 that DRG DNMT1 may be a potential target for neuropathic pain management.SIGNIFICANCE STATEMENT In th

142 ifth lumbar (L5) nerve injury in rats causes neuropathic pain manifested with thermal and mechanical

143 between altered dendritic spine dynamics and neuropathic pain may serve as a structure-based opportun

144 Here, we used a neuropathic pain model of perineural HIV envelope glycop

145 In a neuropathic pain model of perineural HIV gp120 applicati

146 In a neuropathic pain model, LC(:SC) activation reduced hind-

147 r cingulate cortex in a chemotherapy-induced neuropathic pain model.

148 howed significant effects on the CCI-induced neuropathic pain model.

149 tenance of neuropathic nociception in either neuropathic pain model.

150 ute inflammatory pain and paclitaxel-induced neuropathic pain models during cancer chemotherapy.

151 fects in myriad preclinical inflammatory and neuropathic pain models.

152 in the spinal cord in a nerve injury-induced neuropathic pain mouse model.

153 isingly, these striking positive outcomes on neuropathic pain occurred in the absence of any effect o

154 Skin biopsies from patients with neuropathic pain often show changes in epidermal innerva

155 x-specific transcriptome changes, leading to neuropathic pain only in female mice.

156 nged in a sciatic nerve transection model of neuropathic pain or in the Complete Freund's adjuvant mo

157 ical hypersensitivity that characterizes the neuropathic pain phenotype.

158 ting the mechanisms by which HCAR2 regulates neuropathic pain plasticity.

159 arget of rapamycin complex 1 is activated in neuropathic pain pointing to a key role of MNK1-eIF4E-me

160 though it has no major influence on acute or neuropathic pain processing.

161 . x 12 days) suppressed chemotherapy-induced neuropathic pain produced by paclitaxel without producin

162 gonist EHD2-sc-mTNF(R2) in mice with chronic neuropathic pain promoted long-lasting pain recovery.

163 udy therefore reveals a function of TNFR2 in neuropathic pain recovery and demonstrates that both TNF

164 Neuropathic pain remains a therapeutic challenge because

165 e underlying mechanism of MrgprD involved in neuropathic pain remains elusive.

166 the involvement of CB(2) from these cells in neuropathic pain remains unresolved.

167 RGMa antibody also attenuated neuropathic pain responses, which was associated with fe

168 olecular level, the beneficial reductions in neuropathic pain resulting from S1PR1 inhibition were dr

169 neuropathy symptom inventory questionnaire, neuropathic pain scale) and QoL (SF-36, pre-R-ODS and ho

170 These findings also support the use of neuropathic pain screening tools in these patients and t

171 questionnaire, and treatment algorithms for neuropathic pain should now be used in the management of

172 y, we report that individuals with orofacial neuropathic pain show altered functional connectivity be

173 triggers pC/EBPbeta in the HIV gp120-induced neuropathic pain state.

174 pathic pain and may be highly efficacious in neuropathic pain states that are refractive to opioid an

175 l horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersen

176 ion by MRI and patient-based questionnaires (Neuropathic Pain Symptom Inventory and 36-Short Form Hea

177 Neuropathic pain symptoms respond poorly to available th

178 and neuronal plasticity related to radicular/neuropathic pain that may suggest therapeutic avenues an

179 We explored spontaneous neuropathic pain through on-demand self-administration o

180 s essential in cold allodynia in CCI-induced neuropathic pain through the PKA-TRP-A1 pathway.

181 In this study we used a mouse model of neuropathic pain to dissociate these factors.

182 atform for treating pathologies ranging from neuropathic pain to epilepsy.

183 (eFT508) as an important drug candidate for neuropathic pain treatment.

184 agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1.

185 predominant target in metastasis; MMP-9, in neuropathic pain), beta-secretase 1 (BACE-1, an aspartic

186 sm (eg, painful cramps, nociceptive pain, or neuropathic pain).

187 month) spinal cord injury (25 patients with neuropathic pain, 19 pain-free patients) and neuroimagin

188 for neuropathic pain.SIGNIFICANCE STATEMENT Neuropathic pain, a type of moderate to severe chronic p

189 itical role in all modes of inflammatory and neuropathic pain, although the role of HCN3 in nocicepti

190 rgic receptor is a potential drug target for neuropathic pain, Alzheimer disease, and prostate cancer

191 ne contribute to the generation of epilepsy, neuropathic pain, and autism spectrum disorders; thus, i

192 in rats and dogs and was active in anxiety, neuropathic pain, and lower urinary tract models.

193 multiple sclerosis, asthma, atherosclerosis, neuropathic pain, and rheumatoid arthritis.

194 implicated in neurodevelopmental disorders, neuropathic pain, and schizophrenia.

195 al syndromes and diseases, including chronic neuropathic pain, autism, and epilepsy.

196 In the rodent nerve injury model of neuropathic pain, BDNF-mediated loss of inhibition (disi

197 al dysrhythmia is a key pathology of chronic neuropathic pain, but few studies have investigated thal

198 ts long-lasting spinal inhibitory control of neuropathic pain, but its mechanism of action is complic

199 ormer is causally connected with the chronic neuropathic pain, but its mechanisms are poorly understo

200 st line analgesics used to treat SCI-induced neuropathic pain, but their efficacy is very limited.

201 dimorphism in the microglial contribution to neuropathic pain, depletion of DRG macrophages reduces n

202 artial sciatic nerve ligation (PSNL)-induced neuropathic pain, however, the cell types that are funct

203 a potential new target for the treatment of neuropathic pain, including chemotherapy (paclitaxel)-in

204 unctional perceptual changes associated with neuropathic pain, including pain aversion to light touch

205 on of various ion channels can be altered in neuropathic pain, including T-type Ca(2+) channels that

206 In the spared nerve injury (SNI) model of neuropathic pain, NPY-saporin decreased mechanical and c

207 steroidal anti-inflammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical

208 Patients suffering from neuropathic pain, or nerve damage, experience an inversi

209 Given that Kcna2 is a key player in neuropathic pain, our findings suggest that DRG DNMT1 ma

210 ty in vivo in an experimental mouse model of neuropathic pain, raising the possibility that it might

211 old allodynia and models of inflammatory and neuropathic pain, respectively, following intraperitonea

212 adigms in a rat model of oxaliplatin-induced neuropathic pain, showed the better antihypersensitive p

213 aviors in C57BL/6J male mice were induced by neuropathic pain, unpredictable chronic mild stress, and

214 development and/or maintenance of acute and neuropathic pain, we selectively ablated Y1R-expressing

215 In these well-established models of neuropathic pain, we show that the onset of chronic pain

216 T2 represents a valuable strategy to relieve neuropathic pain, we synthesized novel activators (4a-f)

217 us CARTp signaling in spinal cord attenuated neuropathic pain, whereas exogenous intrathecal CARTp ev

218 iors across sensory modalities and abolished neuropathic pain-induced mechanical (hyper-)sensitivity.

219 re severe dry eye symptoms, ocular pain, and neuropathic pain-like ocular symptoms.

220 e blockage of the mGluR5 resulted in chronic neuropathic pain-like symptoms even in the absence of ne

221 regulation, oocyte development, epilepsy and neuropathic pain.

222 pharmacological target to treat SCI-induced neuropathic pain.

223 r synaptic plasticity in the pathogenesis of neuropathic pain.

224 erves (L3 and L4) would alleviate peripheral neuropathic pain.

225 ion mainly produced by fibroblasts, controls neuropathic pain.

226 microglia contribute to nerve injury-induced neuropathic pain.

227 ury and chemotherapy-induced mouse models of neuropathic pain.

228 cause of lower-limb amputation and disabling neuropathic pain.

229 a promising drug target for the treatment of neuropathic pain.

230 ting a potential role in the pathogenesis of neuropathic pain.

231 in chronic constriction injury (CCI)-induced neuropathic pain.

232 on of pain signalling and the maintenance of neuropathic pain.

233 ntial pharmacological target in migraine and neuropathic pain.

234 an potentially be exploited toward targeting neuropathic pain.

235 TRP-A1 facilitates MrgprD to development of neuropathic pain.

236 ntially damaging stimuli, are key drivers of neuropathic pain.

237 the analgesic action of these drugs against neuropathic pain.

238 TSP/alpha(2)delta-1 interaction to alleviate neuropathic pain.

239 nopioid therapy for the treatment of chronic neuropathic pain.

240 elieving effect against nerve injury-induced neuropathic pain.

241 owing promising efficacy in a mouse model of neuropathic pain.

242 for the control of inflammatory, chronic and neuropathic pain.

243 temporomandibular disorders, and trigeminal neuropathic pain.

244 patients with variable presence of radicular/neuropathic pain.

245 Facilitation of MrgprD by TRP-A1 promotes neuropathic pain.

246 acid receptor type 2 (HCAR2) in 2 models of neuropathic pain.

247 trials, eFT508, may be a new therapeutic for neuropathic pain.

248 normalities in Schwann cells (SCs) may cause neuropathic pain.

249 le of Toll-like receptor 4 (TLR4) in driving neuropathic pain.

250 ht to drive aversion associated with chronic neuropathic pain.

251 id receptor type 2 in the pathophysiology of neuropathic pain.

252 ally-directed Y1R agonists to reduce chronic neuropathic pain.

253 h the cognitive and the sensory component of neuropathic pain.

254 which may contribute to nerve injury-induced neuropathic pain.

255 and treatment algorithms designed to target neuropathic pain.

256 hanical hypersensitivity, a major symptom of neuropathic pain.

257 ependent distribution resulting in disabling neuropathic pain.

258 e nociceptive system is a basic mechanism of neuropathic pain.

259 hanical hypersensitivity, a major symptom of neuropathic pain.

260 tic silencing as a new treatment modality in neuropathic pain.

261 ntion of chronic cancer chemotherapy-induced neuropathic pain.

262 the rat chronic constrictive injury model of neuropathic pain.

263 itivity in peripheral nerve injury models of neuropathic pain.

264 odone in pain-free states, and in a model of neuropathic pain.

265 nhibition of Panx1 may be useful in treating neuropathic pain.

266 n the rat spared nerve injury (SNI) model of neuropathic pain.

267 eurological disorders including epilepsy and neuropathic pain.

268 del of peripheral nerve injury (PNI)-induced neuropathic pain.

269 t and the development of novel therapies for neuropathic pain.

270 as modeling human neurological diseases like neuropathic pain.

271 ovel therapeutic target for the treatment of neuropathic pain.

272 Mice deficient in PI16 are protected against neuropathic pain.

273 lue than common outbred strains for modeling neuropathic pain.

274 can cause acute peripheral pain and chronic neuropathic pain.

275 ymal transition (EMT), loss of sensation and neuropathic pain.

276 ied activity of PB neurons in a rat model of neuropathic pain.

277 ndritic spine dysgenesis and the presence of neuropathic pain.

278 ing of LPA(1) signaling in the PSNL model of neuropathic pain.

279 innings in the initiation and maintenance of neuropathic pain.

280 t an interesting therapeutic alternative for neuropathic pain.

281 that protects against spontaneous and evoked neuropathic pain.

282 sence epilepsy, cardiovascular diseases, and neuropathic pain.

283 phage TLR9 signaling in chemotherapy-induced neuropathic pain.SIGNIFICANCE STATEMENT Chemotherapy-ind

284 subunits could be potential drug targets for neuropathic pain.SIGNIFICANCE STATEMENT Neuropathic pain

285 ic cognitive deficits that are comorbid with neuropathic pain.SIGNIFICANCE STATEMENT The medial prefr

286 including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEMENT This work demons

287 therapeutic target against inflammatory and neuropathic pain.SIGNIFICANCE STATEMENT We demonstrate t

288 increased 5-HT2CR in the BLA contributes to neuropathic-pain-related amygdala plasticity by driving

289 r its anxiolytic-like and ability to relieve neuropathic painful conditions evaluated in CCI and STZ

290 aliplatin triggers alterations in peripheral neuropathic pathways previously linked to IL-8 pathway.

291 body, it was tested whether skin cells from neuropathic patients would display the cellular patholog

292 lt K/BxN transgenic arthritic mice display a neuropathic phenotype, an assertion consistent with the

293 plasticity of the brain in DSP driven by the neuropathic process.

294 ace excessive production and accumulation of neuropathic proteins as the major initiating events.

295 reduced measures of allodynia in a chronic, neuropathic sciatic nerve injury model, but tolerance to

296 In humans, CSF spermine was elevated in neuropathic subtypes of MPS (MPS I, II, IIIA, IIIB), but

297 f large and small nerve fibre function, CCM, neuropathic symptoms (small fibre neuropathy symptom inv

298 loss, which correlates with the severity of neuropathic symptoms and reduced QoL in patients with pa

299 ry [Short Form]; and the Leeds Assessment of Neuropathic Symptoms and Signs [Self-Assessment] scale).

300 l CCM parameters and the severity of painful neuropathic symptoms, depression score and QoL.